Table 1.
Baseline Characteristics of 536 Patients With Human Immunodeficiency Virus–Hepatitis C Virus Coinfection Treated with Interferon-Free Direct-Acting Antiviral Regimens, 2014–2017
| Characteristic | Patients, No. (%)a |
|---|---|
| Age, median (range), y | 55 (26–75) |
| Male sex | 426 (79) |
| Race/ethnicity | |
| White | 170 (32) |
| Black | 315 (59) |
| Hispanic | 34 (6) |
| Other | 15 (3) |
| HIV risk factor category | |
| MSM | 132 (25) |
| IDU | 228 (42) |
| MSM and IDU | 74 (14) |
| Heterosexual | 85 (16) |
| Other/unknown | 11 (2)/6 (1) |
| CD4 cell count | |
| <200/μL | 38 (7) |
| 200–499/μL | 205 (38) |
| ≥500/μL | 293 (55) |
| Antiretroviral therapyb | 467 (87) |
| Tenofovir disoproxil fumarate | 270 (58) |
| Dolutegravir | 218 (47) |
| Abacavir | 165 (35) |
| Raltegravir | 95 (20) |
| Darunavir | 91 (19) |
| Efavirenz | 60 (13) |
| Rilpivirine | 56 (12) |
| Atazanavir | 40 (8.6) |
| Cobicistat-elvitegravir | 25 (5.4) |
| HIV RNA <200 copies/mLc | 496 (98) |
| Chronic hepatitis B | 54 (10) |
| Body mass index >30 kg/m2 | 131 (25) |
| Diabetes mellitusd | 105 (20) |
| HCV RNA >6 million IU/mL | 111 (21) |
| Fibrosis-4 index >3.25 | 128 (24) |
| Prior treatment experience | 90 (17) |
| HCV genotype (n = 507) | |
| 1a | 352 (69) |
| 1b | 120 (24) |
| 1 not subtyped | 15 (3) |
| 2 | 7 (1) |
| 3 | 9 (2) |
| 4 | 4 (1) |
| DAA regimen | |
| Ledipasvir-sofosbuvir | 432 (81) |
| Simeprevir + sofosbuvir | 41 (8) |
| Sofosbuvir-velpatasvir | 24 (4) |
| Daclatasvir + sofosbuvir | 14 (3) |
| Ombitasvir-paritaprevir-ritonavir + dasabuvir | 13 (2) |
| Elbasvir-grazoprevir | 12 (2) |
| Concurrent ribavirin | 33 (6) |
| Mental health disorder | |
| Depression and/or anxiety | 374 (70) |
| Psychotic condition | 65 (12) |
| Substance use disorder | |
| Illicit drugs (amphetamine, cocaine, opiate) | 251 (47) |
| At-risk alcohol | 185 (35) |
Abbreviations: DAA, direct-acting antiviral; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IDU, injection drug use; MSM, men who have sex with men.
aData represent no. (%) of patients unless otherwise specified.
bAntiretroviral therapy categories represent the no. (%) of patients with these agents in their regimen among the 467 patients receiving antiretroviral therapy, recorded before DAA start.
cAmong the 508 patients who had HIV RNA level assessed within 1 year of DAA start. The CD4 cell count, HIV and HCV viral levels, and fibrosis-4 index represented the most recent values before the DAA start date.
dDiabetes mellitus was defined as a diagnosis of diabetes mellitus and use of diabetes-related medication, use of diabetes-specific medication, or hemoglobin A1C ≥6.5%.